MedTrace Logo

CTO-PCI in Heart Failure Patients

NCT05632653 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 783

Last updated 2024-09-19

No results posted yet for this study

Summary

The study investigates wheather CTO-PCI improves survival and heart failure related rehospitalization compared to optimal medical therapy (OMT). This hypothesis will be investigated within a large-scaled international, representative, prospective, randomized, controlled, open-label, event-driven, multicentre trial (trial acronym: CTO - Heart Failure) recruiting patients with planned CTO-PCI.

Conditions

Interventions

PROCEDURE

CTO-PCI

Percutaneous coronary intervention (PCI) of a coronary chronic total occlusion (CTO) (CTO-PCI) in patients with systolic heart failure (LVEF \<50%).

Sponsors & Collaborators

  • Herzzentrum Lahr

    collaborator UNKNOWN

  • IHF GmbH - Institut für Herzinfarktforschung

    collaborator OTHER

  • Universitätsmedizin Mannheim

    lead OTHER

Principal Investigators

  • Michael Behnes, Prof. Dr. · Universitätsmedizin Mannheim

  • Kambis Mashayekhi, PD Dr. · MEDICLIN Herzzentrum Lahr

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2030-03-31
Completion
2030-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05632653 on ClinicalTrials.gov